Literature DB >> 8721541

Combination therapy for HIV-1 infection-overview: preclinical and clinical analysis of antiretroviral combinations.

V A Johnson1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8721541     DOI： 10.1016/0166-3542(95)00912-4

Source DB:  PubMed          Journal:  Antiviral Res        ISSN： 0166-3542            Impact factor:   5.970


× No keyword cloud information.
  5 in total

1.  3'-Azido-3'-deoxythymidine (AZT) mediates cross-resistance to nucleoside analogs in the case of AZT-resistant human immunodeficiency virus type 1 variants.

Authors:  E J Arts; M E Quiñones-Mateu; J L Albright; J P Marois; C Hough; Z Gu; M A Wainberg
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103

2.  Chemical barriers to human immunodeficiency virus type 1 (HIV-1) infection: retrovirucidal activity of UC781, a thiocarboxanilide nonnucleoside inhibitor of HIV-1 reverse transcriptase.

Authors:  G Borkow; J Barnard; T M Nguyen; A Belmonte; M A Wainberg; M A Parniak
Journal:  J Virol       Date:  1997-04       Impact factor: 5.103

3.  Novel use of a guanosine prodrug approach to convert 2',3'-didehydro-2',3'-dideoxyguanosine into a viable antiviral agent.

Authors:  Adrian S Ray; Zhenjun Yang; Chung K Chu; Karen S Anderson
Journal:  Antimicrob Agents Chemother       Date:  2002-03       Impact factor: 5.191

4.  Inhibition of human immunodeficiency virus type 1 replication by combination of transcription inhibitor K-12 and other antiretroviral agents in acutely and chronically infected cells.

Authors:  M Okamoto; T Okamoto; M Baba
Journal:  Antimicrob Agents Chemother       Date:  1999-03       Impact factor: 5.191

5.  The impact of multidideoxynucleoside resistance-conferring mutations in human immunodeficiency virus type 1 reverse transcriptase on polymerase fidelity and error specificity.

Authors:  L F Rezende; K Curr; T Ueno; H Mitsuya; V R Prasad
Journal:  J Virol       Date:  1998-04       Impact factor: 5.103
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.